Association of COMT Val158Met polymorphism and breast cancer risk: An updated meta-analysis

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Qin, Xue ^a   Peng, Qiliu ^a,c   Qin, Aiping ^a   Chen, Zhiping ^b   Lin, Liwen ^a   Deng, Yan ^a   Xie, Li ^a   Xu, Juanjuan ^a   Li, Haiwei ^a   Li, Taijie ^a   Li, Shan ^a   Zhao, Jinmin ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c Baise People's Hospital   (China)

Author keywords

Breast cancer; COMT; Meta analysis; Polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE;

BREAST TUMOR; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; ETHNOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; PATHOLOGY; PHENOTYPE; REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CHI-SQUARE DISTRIBUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

MLCS; MLOWN;

EID: 84867077663     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-136     Document Type: Article

References (75)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) 2006, 84(1):16-28.
3. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975, 27(2):135-206.
4. Mannisto PT, Ulmanen I, Lundstrom K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992, 39:291-350.
5. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2. Genomics 1992, 12(4):822-825. 10.1016/0888-7543(92)90316-K, 1572656.
6. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet 1977, 29(2):125-135. 1685255, 848488.
7. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001, 61(18):6716-6722.
8. Goodman JE, Jensen LT, He P, Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 2002, 12(7):517-528. 10.1097/00008571-200210000-00003, 12360102.
9. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997, 57(24):5493-5497.
10. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 1998, 58(10):2107-2110.
11. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A. Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10(6):635-640.
12. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999, 59(19):4870-4875.
13. Wang Q, Li H, Tao P, Wang YP, Yuan P, Yang CX, Li JY, Yang F, Lee H, Huang Y. Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: a case-control study in southwestern China. DNA and cell biology 2011, 30(8):585-595. 10.1089/dna.2010.1195, 21438753.
14. Naushad SM, Pavani A, Rupasree Y, Sripurna D, Gottumukkala SR, Digumarti RR, Kutala VK. Modulatory effect of plasma folate and polymorphisms in one-carbon metabolism on catecholamine methyltransferase (COMT) H108L associated oxidative DNA damage and breast cancer risk. Indian journal of biochemistry & biophysics 2011, 48(4):283-289.
15. Cribb AE, Joy Knight M, Guernsey J, Dryer D, Hender K, Shawwa A, Tesch M, Saleh TM. CYP17, catechol-o-methyltransferase, and glutathione transferase M1 genetic polymorphisms, lifestyle factors, and breast cancer risk in women on Prince Edward Island. The breast journal 2011, 17(1):24-31. 10.1111/j.1524-4741.2010.01025.x, 21129090.
16. Cerne JZ, Pohar-Perme M, Novakovic S, Frkovic-Grazio S, Stegel V, Gersak K. Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer. Journal of gynecologic oncology 2011, 22(2):110-119. 10.3802/jgo.2011.22.2.110, 3152751, 21860737.
17. Mao C, Wang XW, Qiu LX, Liao RY, Ding H, Chen Q. Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls. Breast Cancer Res Treat 2010, 121(3):719-725. 10.1007/s10549-009-0650-4, 20464630.
18. Ding H, Fu Y, Chen W, Wang Z. COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies. Breast Cancer Res Treat 2010, 123(1):265-270. 10.1007/s10549-010-0759-5, 20130981.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558. 10.1002/sim.1186, 12111919.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
21. Kang D. Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women. J Biochem Mol Biol 2003, 36(1):28-34. 10.5483/BMBRep.2003.36.1.028, 12542972.
22. Naushad SM, Reddy CA, Rupasree Y, Pavani A, Digumarti RR, Gottumukkala SR, Kuppusamy P, Kutala VK. Cross-talk between one-carbon metabolism and xenobiotic metabolism: implications on oxidative DNA damage and susceptibility to breast cancer. Cell Biochem Biophys 2011, 61(3):715-723. 10.1007/s12013-011-9245-x, 21792634.
23. Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM. Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer. Zhonghua Wai Ke Za Zhi 2006, 44(19):1310-1313.
24. Wang Q, Wang YP, Li JY, Yuan P, Yang F, Li H. Polymorphic catechol-O-methyltransferase gene, soy isoflavone intake and breast cancer in postmenopausal women: a case-control study. Chin J Cancer 2010, 29(7):683-688. 10.5732/cjc.009.10700, 20591221.
25. Park SK, Yim DS, Yoon KS, Choi IM, Choi JY, Yoo KY, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kang D. Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res Treat 2004, 88(1):55-62. 10.1007/s10549-004-0745-x, 15538046.
26. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Bruning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 2008, 68(14):5997-6005. 10.1158/0008-5472.CAN-08-0043, 2518124, 18632656.
27. Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF. Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol Biomarkers Prev 2006, 15(9):1620-1629. 10.1158/1055-9965.EPI-06-0198, 16985022.
28. Silva SN, Cabral MN, Bezerra de Castro G, Pires M, Azevedo AP, Manita I, Pina JE, Rueff J, Gaspar J. Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed. Oncol Rep 2006, 16(4):781-788.
29. Corder EH, Hefler LA. Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma. Rejuvenation Res 2006, 9(1):56-60. 10.1089/rej.2006.9.56, 16608396.
30. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Toloczko-Grabarek A, Gilbert M, Edler L, Zapatka M, Eils R, Lubinski J, Scott RJ, Hamann U. BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat 2010, 119(1):201-211. 10.1007/s10549-009-0390-5, 19360465.
31. Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, Moorman PG, Boissy RJ, Bell DA. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 1998, 19(11):1943-1947. 10.1093/carcin/19.11.1943, 9855007.
32. Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD. COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 2001, 22(10):1661-1665. 10.1093/carcin/22.10.1661, 11577006.
33. Yim DS, Parkb SK, Yoo KY, Yoon KS, Chung HH, Kang HL, Ahn SH, Noh DY, Choe KJ, Jang IJ, Shin SG, Strickland PT, Hirvonen A, Kang D. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 2001, 11(4):279-286. 10.1097/00008571-200106000-00001, 11434504.
34. Bergman-Jungestrom M, Wingren S. Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. British journal of cancer 2001, 85(6):859-862. 10.1054/bjoc.2001.2009, 2375076, 11556837.
35. Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S, Oya H, Obata Y. Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. International journal of clinical oncology / Japan Society of Clinical Oncology 2001, 6(1):13-18.
36. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Archives of toxicology 2002, 76(11):643-649. 10.1007/s00204-002-0387-x, 12415427.
37. Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMurray JP. A multigene test for the risk of sporadic breast carcinoma. Cancer 2003, 97(9):2160-2170. 10.1002/cncr.11340, 12712467.
38. Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-Sundberg M, Persson I, Magnusson C. Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis 2003, 24(4):681-687. 10.1093/carcin/bgg022, 12727796.
39. Wu AH, Tseng CC, Van Den Berg D, Yu MC. Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res 2003, 63(21):7526-7529.
40. Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, Lin DX. [Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2003, 25(5):453-456.
41. Sazci A, Ergul E, Utkan NZ, Canturk NZ, Kaya G. Catechol-O-methyltransferase Val 108/158 Met polymorphism in premenopausal breast cancer patients. Toxicology 2004, 204(2-3):197-202.
42. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. Journal of the National Cancer Institute 2004, 96(12):936-945. 10.1093/jnci/djh167, 15199113.
43. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MW, Muendlein A, Koelbl H. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 2004, 101(2):264-269. 10.1002/cncr.20361, 15241822.
44. Ahsan H, Chen Y, Whittemore AS, Kibriya MG, Gurvich I, Senie RT, Santella RM. A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat 2004, 85(2):121-131. 10.1023/B:BREA.0000025401.60794.68, 15111770.
45. Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA. Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 2005, 93(3):261-270. 10.1007/s10549-005-5347-8, 16142442.
46. Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, Yu CP, Yu JC, You SL, Chen CJ, Sun CA. Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP) 2005, 14(3):257-261.
47. Lin WY, Chou YC, Wu MH, Jeng YL, Huang HB, You SL, Chu TY, Chen CJ, Sun CA. Polymorphic catechol-O-methyltransferase gene, duration of estrogen exposure, and breast cancer risk: a nested case-control study in Taiwan. Cancer detection and prevention 2005, 29(5):427-432. 10.1016/j.cdp.2005.07.003, 16191465.
48. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005, 14(8):1998-2003. 10.1158/1055-9965.EPI-05-0076, 16103451.
49. Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, Gao YT, Zheng W. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005, 14(2):329-335. 10.1158/1055-9965.EPI-04-0392, 15734954.
50. Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, Wu PE, Shen CY. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. International journal of cancer 2005, 113(3):345-353.
51. Gaudet MM, Bensen JT, Schroeder J, Olshan AF, Terry MB, Eng SM, Teitelbaum SL, Britton JA, Lehman TA, Neugut AI, Ambrosone CB, Santella RM, Gammon MD. Catechol-O-methyltransferase haplotypes and breast cancer among women on Long Island, New York. Breast Cancer Res Treat 2006, 99(2):235-240. 10.1007/s10549-006-9205-0, 16596327.
52. Gallicchio L, Berndt SI, McSorley MA, Newschaffer CJ, Thuita LW, Argani P, Hoffman SC, Helzlsouer KJ. Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC cancer 2006, 6:173. 10.1186/1471-2407-6-173, 1534058, 16808847.
53. Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W. Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan. Breast (Edinburgh, Scotland) 2006, 15(6):754-761.
54. Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H. SNP-SNP interactions in breast cancer susceptibility. BMC cancer 2006, 6:114. 10.1186/1471-2407-6-114, 1522021, 16672066.
55. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA. Association between common variation in 120 candidate genes and breast cancer risk. PLoS genetics 2007, 3(3):e42. 10.1371/journal.pgen.0030042, 1828694, 17367212.
56. Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC, Gramling BA, Shimasaki CD, Jupe ER. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 2007, 109(10):1940-1948. 10.1002/cncr.22634, 17436274.
57. Akisik E, Dalay N. Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer. Journal of clinical laboratory analysis 2007, 21(2):97-102. 10.1002/jcla.20139, 17385677.
58. Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, Shao ZM. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. Journal of cancer research and clinical oncology 2007, 133(12):969-978. 10.1007/s00432-007-0244-7, 17562079.
59. Takata Y, Maskarinec G, Le Marchand L. Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the Multiethnic Cohort. BMC cancer 2007, 7:30. 10.1186/1471-2407-7-30, 1800856, 17295924.
60. Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis IL, Blomqvist C, Nevanlinna H, Ozcelik H. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC cancer 2008, 8:6. 10.1186/1471-2407-8-6, 2254632, 18194538.
61. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2008, 108(1):137-149. 10.1007/s10549-007-9586-8, 17588204.
62. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J. A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 2009, 113(3):585-594. 10.1007/s10549-008-9962-z, 2664827, 18340529.
63. Reding KW, Weiss NS, Chen C, Li CI, Carlson CS, Wilkerson HW, Farin FM, Thummel KE, Daling JR, Malone KE. Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009, 18(5):1461-1467. 10.1158/1055-9965.EPI-08-0917, 2764317, 19383894.
64. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 2010, 119(2):463-474. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.
65. Yadav S, Singhal NK, Singh V, Rastogi N, Srivastava PK, Singh MP. Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women. Disease markers 2009, 27(5):203-210.
66. Shrubsole MJ, Lu W, Chen Z, Shu XO, Zheng Y, Dai Q, Cai Q, Gu K, Ruan ZX, Gao YT, Zheng W. Drinking green tea modestly reduces breast cancer risk. The Journal of nutrition 2009, 139(2):310-316. 2646205,2646205, 19074205.
67. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. International journal of cancer 2009, 125(4):837-843.
68. Moreno-Galvan M, Herrera-Gonzalez NE, Robles-Perez V, Velasco-Rodriguez JC, Tapia-Conyer R, Sarti E. Impact of CYP1A1 and COMT genotypes on breast cancer risk in Mexican women: a pilot study. The International journal of biological markers 2010, 25(3):157-163.
69. Syamala VS, Syamala V, Sheeja VR, Kuttan R, Balakrishnan R, Ankathil R. Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer investigation 2010, 28(3):304-311. 10.3109/07357900902744494, 19863350.
70. Peterson NB, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Huang Y, Chanock SJ, Haines JL, Egan KM. Association of COMT haplotypes and breast cancer risk in caucasian women. Anticancer research 2010, 30(1):217-220. 3086748, 20150638.
71. Delort L, Satih S, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ. Evaluation of breast cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen metabolisms. Nutrition and cancer 2010, 62(2):243-251. 10.1080/01635580903305300, 20099199.
72. Lajin B, Hamzeh AR, Ghabreau L, Mohamed A, Al Moustafa AE, Alachkar A. Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria. Breast cancer (Tokyo, Japan) 2011, Epub ahead of print.
73. dos Santos RA, Teixeira AC, Mayorano MB, Carrara HH, de Andrade J, Takahashi CS. Variability in estrogen-metabolizing genes and their association with genomic instability in untreated breast cancer patients and healthy women. Journal of biomedicine & biotechnology 2011, 2011:571784.
74. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998, 19(1):1-27. 10.1093/carcin/19.1.1, 9472688.
75. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. The New England journal of medicine 1992, 327(4):248-254. 10.1056/NEJM199207233270406, 1614465.